Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose-ranging, randomized, placebo-controlled trial

被引：9
|
作者：
Muir, A. [1 ]
Goodman, Z. [2 ]
Levy, C. [3 ]
Janssen, H. [4 ]
Montano-Loza, A. [5 ]
Bowlus, C. [6 ]
Ding, D. [7 ]
Jia, C. [7 ]
McColgan, B. [7 ]
Myers, R. [7 ]
Subramanian, M. [7 ]
McHutchison, J. [7 ]
Manns, M. [8 ]
Chapman, R. [9 ]
Afdhal, N. [10 ,11 ]
Eksteen, B. [12 ]
机构：
[1] Duke Clin Res Inst, Durham, NC USA
[2] Inova Fairfax Hosp, Falls Church, VA USA
[3] Univ Miami, Miami, FL USA
[4] Univ Toronto, Toronto, ON, Canada
[5] Univ Alberta, Edmonton, AB, Canada
[6] Univ Calif Davis, Sacramento, CA 95817 USA
[7] GILEAD Sci, Foster City, CA USA
[8] Hannover Med Sch, Hannover, Germany
[9] Univ Oxford, Oxford, England
[10] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[11] Harvard Med Sch, Boston, MA USA
[12] Univ Calgary, Calgary, AB, Canada
来源：
JOURNAL OF HEPATOLOGY | 2017年 / 66卷 / 01期
关键词：
D O I：
10.1016/S0168-8278(17)30408-7
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
PS-132
引用
收藏
页码：S73 / S73
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of simtuzumab for the treatment of nonalcoholic steatohepatitis with bridging fibrosis or cirrhosis: results of two phase 2b, dose-ranging, randomized, placebo-controlled trials
    Sanyal, A.
    Abdelmalek, M. F.
    Diehl, A. M.
    Caldwell, S.
    Shiffman, M. L.
    Ghalib, R.
    Lawitz, E.
    Rockey, D. C.
    Schall, R. A.
    Jia, C.
    McColgan, B. J.
    Myers, R.
    Subramanian, G. M.
    McHutchison, J. G.
    Ratziu, V.
    Afdhal, N.
    Goodman, Z.
    Harrison, S. A.
    Bosch, J.
    [J]. JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S54 - S54
  • [2] Linzagolix for treating endometriosis-associated pain: efficacy and safety results from a randomized, placebo-controlled, multinational, phase 2b dose-ranging trial
    Bestel, E.
    Humberstone, A.
    Lecomte, V.
    Dubouloz, R.
    Terrill, P.
    Donnez, J.
    Taylor, H.
    Taylor, R.
    Loumaye, E.
    [J]. HUMAN REPRODUCTION, 2019, 34 : 64 - 64
  • [3] Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
    Papp, K. A.
    Menter, A.
    Strober, B.
    Langley, R. G.
    Buonanno, M.
    Wolk, R.
    Gupta, P.
    Krishnaswami, S.
    Tan, H.
    Harness, J. A.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 (03) : 668 - 677
  • [4] Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study
    Oakes, Tina Marie Myers
    Skljarevski, Vladimir
    Zhang, Qi
    Kielbasa, William
    Hodsdon, Michael E.
    Detke, Holland C.
    Camporeale, Angelo
    Saper, Joel R.
    [J]. CEPHALALGIA, 2018, 38 (06) : 1015 - 1025
  • [5] Phase 2 randomized, placebo-controlled, dose-ranging study to evaluate the safety and efficacy of onabotulinumtoxina for the treatment of platysma prominence
    Rohrich, Rodney
    Bank, David E.
    Bertucci, Vince
    Biesman, Brian S.
    Dayan, Steven
    Humphrey, Shannon
    Jones, Derek
    Kaufman-Janette, Joely
    Muhn, Channy Y.
    Rivers, Jason K.
    Tong, Warren
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB171 - AB171
  • [6] GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus
    Levy, Cynthia
    Kendrick, Stuart
    Bowlus, Christopher L.
    Tanaka, Atsushi
    Jones, David
    Kremer, Andreas E.
    Mayo, Marlyn J.
    Haque, Nazneen
    von Maltzahn, Robyn
    Allinder, Matthew
    Swift, Brandon
    McLaughlin, Megan M.
    Hirschfield, Gideon M.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (07) : 1902 - +
  • [7] Ianalumab (VAY736) Safety and Efficacy in Patients with Sjogren's Syndrome: 52 Week Results from a Randomized, Placebo-controlled, Phase 2b Dose-ranging Trial
    Doerner, Thomas
    Bowman, Simon J.
    Fox, Robert
    Mariette, Xavier
    Papas, Athena
    Grader-Beck, Thomas
    Fisher, Ben A.
    Barcelos, Filipe
    De Vita, Salvatore
    Schulze-Koops, Hendrik
    Moots, Robert
    Junge, Guido
    Woznicki, Janice
    Sopala, Monika
    Luo, Wen-Lin
    Hueber, Wolfgang
    [J]. ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2063 - 2065
  • [8] IANALUMAB (VAY736) SAFETY AND EFFICACY IN PATIENTS WITH SJOGREN'S SYNDROME: 52 WEEK RESULTS FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2B DOSE-RANGING TRIAL
    Doerner, T.
    Bowman, S. J.
    Fox, R.
    Mariette, X.
    Papas, A.
    Grader-Beck, T.
    Fisher, B. A.
    Barcelos, F.
    De Vita, S.
    Schulze-Koops, H.
    Moots, R. J.
    Junge, G.
    Woznicki, J.
    Sopala, M.
    Luo, W.
    Hueber, W.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2022, 40 (12) : 87 - 88
  • [9] Iscalimab (CFZ533) in Patients with Sjogren's Disease: Week 24 Efficacy and Safety Results of a Randomized, Placebo-controlled, Phase 2b Dose-ranging Study
    Fisher, Benjamin A.
    Mariette, Xavier
    Papas, Athena S.
    Grader-Beck, Thomas
    Bootsma, Hendrika
    Ng, Wan-Fai
    Van Daele, Paul
    Finzel, Stephanie
    Elgueta, Sergio
    Hermann, Josef
    McCoy, Sara
    Bookman, Arthur
    Sopala, Monika
    Luo, Wen-Lin
    Scheurer, Cornelia
    Hueber, Wolfgang
    [J]. ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 3242 - 3244
  • [10] Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial
    Dubourg, Julie
    Ueki, Kohjiro
    Grouin, Jean-Marie
    Fouqueray, Pascale
    [J]. DIABETES OBESITY & METABOLISM, 2021, 23 (03): : 800 - 810
12345